Transcept's drug for obsessive compulsive disorder fails trial
(Reuters) - Transcept Pharmaceuticals Inc said a mid-stage trial of its experimental drug for obsessive compulsive disorder did not meet the main goal of showing improvements in treating symptoms better than a placebo.
The company expects to complete the remaining analyses in early 2013 and will decide on the future development of the drug, TO-2061, after further review of the data.
The trial was testing the drug in patients with obsessive compulsive disorder who had not adequately responded to treatment with approved first-line therapies.
(Reporting by Esha Dey in Bangalore; Editing by Don Sebastian)
- Police seek motive in fatal Washington state school shooting
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Washington state teen shooter's family living in 'nightmare'
- Two deputies killed, two others hurt in California shooting spree
- Wall St. finally turning on Amazon as Bezos magic fades